Surgery Combined with Long-Term Imatinib Treatment for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors

2020 ◽  
Author(s):  
Chunhui Shou ◽  
Qing Gao ◽  
Weili Yang ◽  
Qing Zhang ◽  
Xiaosun Liu ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Imatinib Treatment ◽  
Stromal Tumors

scholarly journals Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam

2019 ◽  
Vol 26 (1) ◽  
pp. 107327481986377 ◽  
Author(s):  
Kien Do Hung ◽  
Quang Le Van ◽  
Gia Nguyen Hoang ◽  
Phuong Nguyen Thi Bich
Keyword(s):  
Imatinib Mesylate ◽  
Gastrointestinal Stromal Tumors ◽  
Performance Status ◽  
Progression Free Survival ◽  
High Response Rate ◽  
Imatinib Treatment ◽  
Middle Income ◽  
Stromal Tumors ◽  
Asian Patients

Only limited data are available concerning the long-term outcomes of imatinib treatment among Vietnamese or Asian patients with unresectable or recurrent gastrointestinal stromal tumors (GISTs). Our study, which was conducted in 188 patients, aimed to assess the efficacy of imatinib mesylate against unresectable or recurrent GISTs. Imatinib had a high response rate and long survival. Some predictors favorable for progression-free survival and overall survival are good performance status and response with imatinib. Findings are discussed in relation to clinical practice in low- and middle-income country.

scholarly journals Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors

Digestion ◽  
2018 ◽  
Vol 97 (1) ◽  
pp. 20-25 ◽  
Author(s):  
Kyoichi Ogata ◽  
Akiharu Kimura ◽  
Nobuhiro Nakazawa ◽  
Masaki Suzuki ◽  
Toru Yanoma ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Imatinib Treatment ◽  
Stromal Tumors

A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors

2014 ◽  
Vol 110 (8) ◽  
pp. 942-946 ◽  
Author(s):  
Kyoichi Ogata ◽  
Erito Mochiki ◽  
Hitoshi Ojima ◽  
Norihiro Haga ◽  
Minoru Fukuchi ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Japanese Patients ◽  
Imatinib Treatment ◽  
Term Study ◽  
Stromal Tumors ◽  
Long Term Study

Long-term and surgical outcomes of laparoscopic surgery for gastric gastrointestinal stromal tumors

2014 ◽  
Vol 28 (8) ◽  
pp. 2317-2322 ◽  
Author(s):  
Michitaka Honda ◽  
Naoki Hiki ◽  
Souya Nunobe ◽  
Manabu Ohashi ◽  
Takashi Kiyokawa ◽  
...  
Keyword(s):  
Laparoscopic Surgery ◽  
Surgical Outcomes ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors

Long-term outcomes of percutaneous endoscopic intragastric surgery in the treatment of gastrointestinal stromal tumors at the esophagogastric junction

2015 ◽  
Vol 30 (5) ◽  
pp. 2036-2042 ◽  
Author(s):  
Eiji Kanehira ◽  
Aya Kamei ◽  
Akiko Umezawa ◽  
Atsushi Kurita ◽  
Takashi Tanida ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Esophagogastric Junction ◽  
Long Term Outcomes ◽  
Stromal Tumors ◽  
Intragastric Surgery

scholarly journals Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis

2016 ◽  
Vol 10 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Ryota Niikura ◽  
Takako Serizawa ◽  
Atsuo Yamada ◽  
Shuntaro Yoshida ◽  
Mariko Tanaka ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Imatinib Treatment ◽  
Efficacy And Safety ◽  
Tarry Stool ◽  
Dialysis Patients ◽  
Stromal Tumors ◽  
Duodenal Gist ◽  
Johnson Syndrome ◽  
Old Japanese ◽  
Steven Johnson Syndrome

The number of cancer patients undergoing dialysis has been increasing, and the number of these patients on chemotherapy is also increasing. Imatinib is an effective and safe therapy for KIT-positive gastrointestinal stromal tumors (GIST), but the efficacy and safety of imatinib in dialysis patients remain unclear. Because clinical trials have not been conducted in this population, more investigations are required. We report on a 75-year-old Japanese man undergoing dialysis who presented with massive tarry stool from a duodenal GIST. The duodenal GIST was 14 cm in diameter with multiple liver and bone metastases. The patient underwent an urgent pancreaticoduodenectomy to achieve hemostasis. After surgery, he was administered imatinib 400 mg/day. No severe adverse event including myelosuppression, congestive heart failure, liver functional impairment, intestinal pneumonia, or Steven-Johnson syndrome occurred, and the liver metastasis remained stable for 4 months. During chemotherapy, hemodialysis continued three times per week without adverse events. We suggest that regular-dose imatinib is an effective and safe treatment in patients with GIST undergoing dialysis. In addition, we present a literature review of the effectiveness and safety of imatinib treatment in dialysis patients.

Long-term Survival among Patients with Gastrointestinal Stromal Tumors Diagnosed after Another Malignancy: A SEER Population-Based Study

2020 ◽  
Author(s):  
Chaoyong Shen ◽  
Chengshi Wang ◽  
Tao He ◽  
Zhaolun Cai ◽  
Xiaonan Yin ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Population Based ◽  
Clinicopathological Characteristics ◽  
Second Primary ◽  
Primary Malignancy ◽  
Clinicopathologic Characteristics ◽  
Term Survival ◽  
Stromal Tumors ◽  
Group A

Abstract BACKGROUND: To explore overall survival (OS) and GISTs-specific survival (GSS) among cancer survivors developing a second primary gastrointestinal stromal tumors (GISTs). METHODS: We conducted a cohort study, where patients with GISTs after another malignancy (AM-GISTs, n=851) and those with only GISTs (GISTs-1, n=7660) were identified from the Surveillance, Epidemiology, End Results registries (1988-2016). Clinicopathologic characteristics and survival were compared between the two groups. RESULTS: The most commonly diagnosed first primary malignancy was prostate cancer (27.7%), followed by breast cancer (16.2%). OS among AM-GISTs was significantly inferior to that of GISTs-1: 10-year OS was 40.3% vs. 50.0%, (p<0.001); A contrary finding was observed for GSS (10-year GSS: 68.9% vs. 61.8%, p=0.002). In the AM-GISTs group, a total of 338 patients died, of which 26.0% died of their initial cancer and 40.8% died of GISTs. Independent of demographics and clinicopathological characteristics, mortality from GISTs among AM-GISTs patients was decreased compared with their GISTs-1 counterparts (HR, 0.71; 95% CI, 0.59-0.84; p<0.001); whereas OS was inferior among AM-GISTs (HR, 1.11; 95% CI, 0.99-1.25; p=0.085). CONCLUSIONS: AM-GISTs patients have decreased risk of dying from GISTs compared with GIST-1. Although another malignancy history does not seemingly affect OS for GISTs patients, clinical treatment of such patients should be cautious.

Sign in / Sign up

Export Citation Format

Share Document